Intravitreal triamcinolone and bevacizumab are emerging treatment modalities for the
patients of macular oedema; however, they are known to raise intraocular pressure. A 61 year old
diabetic male patient developed glaucoma after administration of triamcinolone acetonide and
bevacizumab intravitreally for treatment of macular oedema. His intraocular pressure was raised up to
about 42 mm Hg. Such high and sustained rise in intraocular pressure may lead to vision loss by
damaging the optic nerve. The patient was managed by local as well as systematic therapy and was
recovered after 1 month from the occurrence of an event. Intraocular pressure should be monitored in
patients receiving intravitreal triamcinolone and bevacizumab. Risk benefit analysis must be done
before using IVTA and IVB in patients with diabetic macular oedema.
Keywords: Triamcinolone acetonide, bevacizumab, intraocular pressure, diabetes mellitus, adverse drug reaction.
Rights & PermissionsPrintExport